Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients.
52W Range
40thpctl
Volume
0.08×avg
Market Cap
59.18MUSD
P/E Ratio
-6.0TTM
Div Yield
-ann
Loading chart data...
Current StateState loading
Xilio Therapeutics, Inc.
XLONASDAQ Global Select·USD·Closed
Xilio Therapeutics, Inc.
XLONASDAQ·USD·Closed
$9.00
+0.90%
$9.00
+$0.08 (0.90%)
52W Range
40thpctl
Volume
0.08×avg
Mkt Cap
59.18MUSD
P/E
-6.0TTM
Div Yield
–ann
XLO: Xilio Therapeutics, Inc. Stock Analysis | finqOS
